Everest Medicines Limited (HKG:1952)

Market Cap	10.61B -33.8%
Revenue (ttm)	1.90B +141.5%
Net Income	-331.36M
EPS	-0.99
Shares Out	351.47M
PE Ratio	n/a
Forward PE	45.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	628,679
Open	30.88
Previous Close	30.20
Day's Range	29.18 - 30.88
52-Week Range	27.00 - 77.55
Beta	1.54
Analysts	Buy
Price Target	49.72 (+69.46%)
Earnings Date	Mar 26, 2026

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 812
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1952

Financial Performance

In 2025, Everest Medicines's revenue was 1.71 billion, an increase of 141.51% compared to the previous year's 706.68 million. Losses were -297.77 million, -71.41% less than in 2024.

Financial numbers in CNY